NIMG-39. REVEALING THE TUMOR-IMMUNE LANDSCAPE THROUGH SPATIALLY-RESOLVED RADIOMICS: CASE STUDIES. (11th November 2019)

• Record Type: Journal Article
• Authors: Hawkins-Daarud, Andrea; Yoon, Hyunsoo; Monie, Dileep; Singleton, Kyle; Ranjbar, Sara; Tran, Nhan; Badie, Behnam; Rockne, Russell; Brown, Christine E; Hu, Leland; Bruce, Jeff; Canoll, Peter D; Li, Jing; Swanson, Kristin
• Is Part Of: Neuro-oncology. Volume 21(2019)Supplement 6
• Page Start: vi169
• Page End: vi170
• Publication Date: 2019-11-11
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noz175.709
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: Conventional magnetic resonance imaging (MR) guides patient care in GBM. However, there is mounting awareness that MR enhancement is non-specific reflecting either tumor progression or non-tumoral inflammatory changes. Histological evaluation of GBM is held as the gold standard for disease assessment. However, the invasiveness of this methodology and the sample sparsity limit its usefulness. Methods to infer histological underpinnings of MRI are needed to improve clinical care. METHODS: A transfer learning mixed effects model based on T1Gd and FLAIR MR voxel based image features trained and cross-validated to predict FPKM values of CD68, CASP3, CD8A and IL13RA2. Training data included RNAseq from 38 image-localized biopsies from 15 newly-diagnosed GBM patients. These models were then applied to two independent patients, chosen based on therapy and the quality of image registration, at three different time points, just prior to receiving IL13RA2 targeted CAR-T therapy for rGBM, after 2 cycles and after 4 cycles, resulting in a voxel-based prediction of the relative expression levels of these genes. RESULTS: Cross-validation of the proposed machine learning models demonstrated a Pearson Correlation coefficient between predicted and observed FPKM values of 0.89 (CD68), 0.92 (CASP3), 0.93 (CD8A), and 0.88 (IL13RA2). When the models were applied to the two CAR-T patients, CD68-modeled expression levels were seen to increase throughout therapy for one patient, while remaining stable for the other. Survival from first CAR-T infusion was, respectively, 412 and 83 days suggesting that the increased CD68 was indicative of therapeutic effectivity. Further, the spatial activity predictions were consistent with expected therapeutic action as the correlation coefficient between CASP3 and the product of IL13R2 and CD8A expression was 0.81, suggesting the T-cells targeting IL13RA2 were inducing cell death. CONCLUSIONS: Preliminary results with our model highlights the potential of spatially resolved radiomic maps to provide insight into regional therapeutic effectivity.